Pasithea Therapeutics Snubs Takeover Bid, OKs $4M Share Buyback Plan
- July 20th, 2023
- 332 views
Pasithea Therapeutics Corp. (Nasdaq: KTTA) has authorized a $4.0 million share repurchase plan (through a tender offer), to buy approximately 5.7 million shares of its outstanding common stock at $0.70 per share.
The company's executive officers and directors won't tender any shares in the offer. If oversubscribed, the repurchase will be done on a pro rata basis.
In addition, Pasithea confirmed the rejection of an unsolicited proposal from Lucy Scientific Discovery, Inc. (Nasdaq: LSDI) to acquire all outstanding shares of Pasithea common stock for $0.60 in cash plus $0.25 worth of Lucy common stock.
Following a comprehensive review with independent advisors, Pasithea's Special Committee deemed the proposal inadequate, stating it doesn't reflect the company's strategic value and growth prospects.
$KTTA was trading at $0.58 in pre-market, up $0.11 (+22.21%) after the announcements.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
NJCP National Football Conference Names David Dalton Head Coach of Salt Lake Yeti
February 06th, 2026FDA Takes New Approach to "No Artificial Colors" Claims
February 06th, 2026NJCP National Football Conference Announces Micah Deckart as Head Coach of the Idaho Outlaws
February 05th, 2026
Member Login